Inhibikase Therapeutics, Inc. - Common Stock (IKT)

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Inhibikase Therapeutics shares are trading higher by 50% during Wednesday's session. The company announced the pricing of an approximately $110 million private placement financing.

IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. Dermata Therapeutics shares jumped 57.3% to $0.9601 in pre-market trading.

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.